Prognostic importance of p53 and c-erbB-2 oncoproteins overexpression in patients with breast cancer.

Using immunohistochemistry, 119 breast cancer tissues were examined for overexpression of p53 and c-erbB-2 oncogene proteins. In 46 (38.7%) of the cases p53 was overexpressed, while 35 (29.

Incidence of childhood cancer in Thailand 1988-1991.

Incidence rates of cancers of childhood in Thailand are presented for the first time, and compared with results from cancer registries in Asia, Europe and the USA. As elsewhere in the world, leukaemia (principally acute lymphocytic), brain tumours and lymphomas comprise two-thirds of all childhood neoplasms. Carcinomas are rare, but the principal sites (liver, nasopharynx, thyroid and salivary gland) are extremely unusual elsewhere.

Cancer incidence in Thailand, 1988-1991.

Results from three cancer registries (Chiang Mai, Khon Kaen, and Songkhla) in different regions of Thailand and from a cancer survey in the population of Bangkok during the years 1988-1991 are presented, together with an estimate of the incidence of cancer for the country as a whole. Overall, liver cancer is the most frequent malignancy, but there are large regional differences in incidence and in histological type, with very high rates of cholangiocarcinoma in the northeast (associated with endemic opisthorchiasis) but a more even distribution of hepatocellular carcinoma. Lung cancer is second in frequency, with the highest rates in northern Thailand, where the incidence in women (Age Standardized Rate, 37.

Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.

Ondansetron in the prophylaxis of Cisplatin-induced emesis and nausea. The 5-HT3 antagonist ondansetron clearly offers a new approach to the control of Cisplatin-induced emesis and has been evaluated in Thailand. To evaluate anti-emetic efficacy of ondansetron in the prevention of nausea and vomiting induced by Cisplatin containing cancer chemotherapy regimen, we carried out an open multicentre study from January 1991 to December 1992.

Five years survival result of twenty-two breast cancers treated by breast conserving therapy at NCI Bangkok.

From November 1984 to July 1992 Breast Conserving Therapy (BCT) has been offered to clinical stage 1 & 2 breast cancers. Twenty two breast cancers were treated and passed the five year period. Only one patient was lost in follow-up.